Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy

被引：0
|
作者：
Grovdal, Michael [1 ]
Khan, Rasheed [1 ]
Aggerholm, Anni [2 ,3 ]
Antunovic, Petar
Astermark, Jan [4 ]
Bernell, Per [5 ]
Engstroem, Lena-Maria [6 ]
Kjeldsen, Lars [7 ]
Linder, Olle [8 ]
Nilsson, Lars [9 ]
Olsson, Anna [10 ]
Wallvik, Jonas [11 ]
Tangen, Jon Magnus [12 ]
Oeberg, Gunnar [13 ]
Jacobsen, Sten Eirik [9 ]
Porwit, Anna [14 ]
Hokland, Peter [2 ]
Helistrom-Lindberg, Eva [1 ]
机构：
[1] Karolinska Univ, Huddinge Hosp, Karolinska Inst, Stockholm, Sweden
[2] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
[3] Linkoping Univ Hosp, S-58185 Linkoping, Sweden
[4] Malmo Univ Hosp MAS, Malmo, Sweden
[5] Karolinska Univ Hosp, Stockholm, Sweden
[6] Univ Hosp Norrland NUS, Umea, Sweden
[7] Rigshosp, DK-2100 Copenhagen, Denmark
[8] Orebro Univ Hosp, Orebro, Sweden
[9] Univ Lund Hosp, S-22185 Lund, Sweden
[10] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden
[11] Sundsvall Hosp, Sundsvall, Sweden
[12] Ullevaal Univ Hosp, Oslo, Norway
[13] Uppsala Acad Hosp, Uppsala, Sweden
[14] Dept Pathol, Stockholm, Sweden
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：89 / 89
页数：1
相关论文
共 50 条
  • [1] Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (MDS-AML) in complete remission (CR) after induction chemotherapy
    Groevdal, M.
    Kahn, R.
    Jansson, M.
    Aggerholm, A.
    Antunovic, P.
    Astermark, J.
    Bernell, P.
    Engstroem, L.
    Kjeldsen, L.
    Linder, O.
    Nilsson, L.
    Olsson, A.
    Skovholm, M.
    Tangen, J.
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S49 - S50
  • [2] Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
    Grovdal, Michael
    Karimi, Mohsen
    Khan, Rasheed
    Aggerholm, Anni
    Antunovic, Petar
    Astermark, Jan
    Bernell, Per
    Engstrom, Lena-Maria
    Kjeldsen, Lars
    Linder, Olle
    Nilsson, Lars
    Olsson, Anna
    Holm, Mette S.
    Tangen, Jon M.
    Wallvik, Jonas
    Oberg, Gunnar
    Hokland, Peter
    Jacobsen, Sten E.
    Porwit, Anna
    Hellstrom-Lindberg, Eva
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (03) : 293 - 302
  • [3] Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)
    Kyo, Taiichi
    Yoshida, Noriaki
    Kyo, Kouhei
    Okatani, Takeshi
    Itagaki, Mitsuhiro
    Yuasa, Hiromi
    Iwato, Koji
    Asaoku, Hideki
    Katayama, Yuuta
    [J]. BLOOD, 2010, 116 (21) : 1209 - 1210
  • [4] Combined chemotherapy for patients with high risk myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS.
    Shi, J
    Shao, ZH
    Liu, H
    Chen, GB
    Zhang, YZ
    Bai, J
    He, GS
    Fu, R
    Zhao, MF
    Cao, YR
    Wu, YH
    Jing, LP
    Hao, YS
    Yang, TY
    [J]. BLOOD, 2003, 102 (11) : 13B - 13B
  • [5] Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine
    Kuendgen, Andrea
    Mueller-Thomas, Catharina
    Urbaniak, Petra
    Lauseker, Michael
    Haferlach, Torsten
    Alpermann, Tamara
    Albuquerque, Andreia
    Kohlmann, Alexander
    Schnittger, Susanne
    Hildebrandt, Barbara
    Royer-Pokora, Brigitte
    Gattermann, Norbert
    Haas, Rainer
    Germing, Ulrich
    Goetze, Katharina
    [J]. BLOOD, 2013, 122 (21)
  • [6] Results of 5-azacitidine therapy in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)
    Freyrie, A.
    Reda, G.
    Vincenti, D.
    Ferla, V.
    Orofino, N.
    Sciume, M.
    Guidotti, F.
    Cortelezzi, A.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S157 - S158
  • [7] Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) following treatment for ovarian cancer
    Gupta, B.
    Sait, S. N.
    Block, A. W.
    Ford, L. A.
    Moysich, K. B.
    Baer, M. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Acute myelogenous leukemia (AML) type induction chemotherapy for the patients with myelodysplastic syndrome (MDS)
    Kim, D.-Y.
    Kim, J.-S.
    Kim, B.-S.
    Bang, S.-M.
    Kim, I.
    Yoon, S.-S.
    Park, S.
    Kim, B. K.
    [J]. LEUKEMIA RESEARCH, 2007, 31 : S138 - S138
  • [9] A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    DiNardo, Courtney D.
    Olin, Rebecca
    Ishizawa, Jo
    Sumi, Hiroyuki
    Xie, Jingdong
    Kato, Kazunobu
    Kumar, Prasanna
    Andreeff, Michael
    [J]. BLOOD, 2019, 134
  • [10] 5-AZACITIDINE MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK AML AND MDS
    Puglisi, Bruna
    Saraceni, Francesco
    Guerzoni, Selene
    Scortechini, Ilaria
    Mancini, Giorgia
    Fiorentini, Alessandro
    Lotito, Antonio
    Colaneri, Francesca Romana
    Federici, Irene
    Olivieri, Attilio
    [J]. BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 364 - 365
12345